What does BAUSCH & LOMB PHARMA do?

BAUSCH & LOMB PHARMA is a wholesaler in Wavre. Public Limited, started on 19 December 1989, 2 establishments.

What is the address of BAUSCH & LOMB PHARMA?

The registered office of BAUSCH & LOMB PHARMA is located at Place Alphonse Bosch 19 box 2, 1300 Wavre.

Is BAUSCH & LOMB PHARMA still active?

Yes. According to the CBE (30 October 2026) BAUSCH & LOMB PHARMA is active, legal situation “Normale toestand”, started on 19 December 1989.

Is BAUSCH & LOMB PHARMA registered on Peppol?

Yes, BAUSCH & LOMB PHARMA is registered on the Peppol network with ID 0208:0439621618.

What is the enterprise number of BAUSCH & LOMB PHARMA?

The enterprise number of BAUSCH & LOMB PHARMA is BE0439621618.

When was BAUSCH & LOMB PHARMA founded?

BAUSCH & LOMB PHARMA was founded on 19 December 1989.

Who are the directors of BAUSCH & LOMB PHARMA?

According to the 2025 annual accounts, the directors of BAUSCH & LOMB PHARMA are: Manoj Kumar PANDA, Pierre GUIBOURG, Eberhard KUEHNE.

Is BAUSCH & LOMB PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 19 December 1989; 5 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account; 2 establishments in the CBE.

How much profit did BAUSCH & LOMB PHARMA make in 2025?

BAUSCH & LOMB PHARMA posted a profit after taxes of € 871,860 in financial year 2025.

What is the revenue of BAUSCH & LOMB PHARMA?

In its most recent annual accounts (2025), BAUSCH & LOMB PHARMA reported revenue of € 37,404,611.

How much does an employee at BAUSCH & LOMB PHARMA earn?

The average wage cost per full-time employee at BAUSCH & LOMB PHARMA was € 123,700 in 2025: staff costs of € 1.4 million for 11.6 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does BAUSCH & LOMB PHARMA have?

According to the 2025 annual accounts, BAUSCH & LOMB PHARMA has 11.6 full-time equivalents (FTE).

BAUSCH & LOMB PHARMA (Public Limited) - Wavre

Dossier BAUSCH & LOMB PHARMA, printed on 30 October 2026 from databakkes.be/en/0439621618/bausch-lomb-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

BAUSCH & LOMB PHARMA from Wavre, company number BE0439621618, closed financial year 2025 with a result of € 871,860 after tax. For that financial year BAUSCH & LOMB PHARMA recorded revenue of € 37.4 million and equity of € 751,241. Compared with financial year 2024, the result moved from € 1 million to € 871,860. The company is profitable. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 6, 2026.

What it is worth Healthy

€ 751,241

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 871,860

▼ 13% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 996,878

▲ 31% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 871,860 paid out

100 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Full-time equivalents

11.6

▲ 0.3 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost Staff costs are payroll only. Director pay sits with services and miscellaneous goods: € 4.6 million in 2025, together with rent, insurance, accountants and other services. The accounts do not split that further.

€ 1.4 million

▼ 6% vs 2024

€ 123,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 7 million

▲ 26% vs 2024

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 74 days on average.

Taxes and wages

€ 477,314

▼ 24% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 29,426,532 Revenue 2022: € 29,426,532 First fiscal year in the series	€ 30,394,109 Revenue 2023: € 30,394,109 ▲ 3% vs 2022 (€ 29,426,532) Favourable step	€ 35,712,415 Revenue 2024: € 35,712,415 ▲ 17% vs 2023 (€ 30,394,109) Favourable step	€ 37,404,611 Revenue 2025: € 37,404,611 ▲ 5% vs 2024 (€ 35,712,415) Favourable step	▲ 5%
Profit after taxes	€ 449,627 Profit after taxes 2022: € 449,627 First fiscal year in the series	€ 693,191 Profit after taxes 2023: € 693,191 ▲ 54% vs 2022 (€ 449,627) Favourable step	€ 1,002,946 Profit after taxes 2024: € 1,002,946 ▲ 45% vs 2023 (€ 693,191) Favourable step	€ 871,860 Profit after taxes 2025: € 871,860 ▼ 13% vs 2024 (€ 1,002,946) Unfavourable step	▼ 13%
Equity	€ 751,241 Equity 2022: € 751,241 First fiscal year in the series	€ 751,241 Equity 2023: € 751,241 Unchanged (€ 751,241) Unchanged	€ 751,241 Equity 2024: € 751,241 Unchanged (€ 751,241) Unchanged	€ 751,241 Equity 2025: € 751,241 Unchanged (€ 751,241) Unchanged
Total debts	€ 7,171,210 Total debts 2022: € 7,171,210 First fiscal year in the series	€ 13,920,358 Total debts 2023: € 13,920,358 ▲ 94% vs 2022 (€ 7,171,210) Unfavourable step	€ 7,323,300 Total debts 2024: € 7,323,300 ▼ 47% vs 2023 (€ 13,920,358) Favourable step	€ 8,347,142 Total debts 2025: € 8,347,142 ▲ 14% vs 2024 (€ 7,323,300) Unfavourable step	▲ 14%
Cash	€ 1,249,719 Cash 2022: € 1,249,719 First fiscal year in the series	€ 691,206 Cash 2023: € 691,206 ▼ 45% vs 2022 (€ 1,249,719) Unfavourable step	€ 761,147 Cash 2024: € 761,147 ▲ 10% vs 2023 (€ 691,206) Favourable step	€ 996,878 Cash 2025: € 996,878 ▲ 31% vs 2024 (€ 761,147) Favourable step	▲ 31%
Retained profit	€ 68,295 Retained profit 2022: € 68,295 First fiscal year in the series	€ 68,295 Retained profit 2023: € 68,295 Unchanged (€ 68,295) Unchanged	€ 68,295 Retained profit 2024: € 68,295 Unchanged (€ 68,295) Unchanged	€ 68,295 Retained profit 2025: € 68,295 Unchanged (€ 68,295) Unchanged
Dividend	€ 449,627 Dividend 2022: € 449,627 First fiscal year in the series	€ 693,191 Dividend 2023: € 693,191 ▲ 54% vs 2022 (€ 449,627) Unchanged	€ 1,002,946 Dividend 2024: € 1,002,946 ▲ 45% vs 2023 (€ 693,191) Unchanged	€ 871,860 Dividend 2025: € 871,860 ▼ 13% vs 2024 (€ 1,002,946) Unchanged	▼ 13%
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 1,512,367 Bank debt 2023: € 1,512,367 Unchanged (€ 0) Unfavourable step	€ 125,327 Bank debt 2024: € 125,327 ▼ 92% vs 2023 (€ 1,512,367) Favourable step	€ 0 Bank debt 2025: € 0 ▼ 100% vs 2024 (€ 125,327) Favourable step	▼ 100%
Balance sheet total	€ 8,067,109 Balance sheet total 2022: € 8,067,109 First fiscal year in the series	€ 14,809,050 Balance sheet total 2023: € 14,809,050 ▲ 84% vs 2022 (€ 8,067,109) Unchanged	€ 8,074,541 Balance sheet total 2024: € 8,074,541 ▼ 45% vs 2023 (€ 14,809,050) Unchanged	€ 9,168,584 Balance sheet total 2025: € 9,168,584 ▲ 14% vs 2024 (€ 8,074,541) Unchanged	▲ 14%
Employees (FTE)	11.8 Employees (FTE) 2022: 11.8 First fiscal year in the series	12.1 Employees (FTE) 2023: 12.1 ▲ 0.3 vs 2022 (11.8) Unchanged	11.3 Employees (FTE) 2024: 11.3 ▼ 0.8 vs 2023 (12.1) Unchanged	11.6 Employees (FTE) 2025: 11.6 ▲ 0.3 vs 2024 (11.3) Unchanged	▲ 0.3

Key figures of BAUSCH & LOMB PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to BAUSCH & LOMB PHARMA?

What happened at BAUSCH & LOMB PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2029 Eberhard KUEHNE stepped down as director. NBB
2028 Manoj Kumar PANDA stepped down as director. NBB
2028 Pierre GUIBOURG stepped down as director. NBB
Jul 6, 2026 New annual accounts for financial year 2025: profit of € 871,860 (▼ 13% vs 2024). Source: NBB ↗
2023 Eberhard KUEHNE became a director. NBB
2022 Manoj Kumar PANDA became a director. NBB
Sep 1, 2022 New establishment in Aalst. KBO
2022 Pierre GUIBOURG became a director. NBB

In short

From € 449,627 profit in 2022 to € 871,860 profit in 2025.

Paid € 1.2 million in corporate taxes since 2022.

Best year ever: 2024, with € 1 million profit.

Paid out € 3 million in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Directors

According to the 2025 annual accounts

Manoj Kumar PANDA

Director

since 2022 · until 2028

Pierre GUIBOURG

Director

since 2022 · until 2028

Eberhard KUEHNE

Director

since 2023 · until 2029

Establishments

Establishment units

Physical locations of this company

Registered office

Place Alphonse Bosch 19 box 2

1300 Wavre

2.383.016.321

Korte Keppestraat 19

9320 Aalst

Active since 1 September 2022

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.

All companies at this address →

BMA

€ 147,588 gross margin · 2025

NEXT ITGEN

€ 23,085 gross margin · 2024

ANFIRI

€ -2,412 gross margin · 2025

Association des copropriétaires "Alphonse Bosch 19" à Wavre, Place Alphonse Bosch 19

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0439.621.618

VAT number

BE 0439.621.618

Registered office

Place Alphonse Bosch 19 bus 2, 1300 Wavre

Names & denominations

BAUSCH & LOMB PHARMA

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

19 December 1989

Peppol

Active · Active since 22 Dec 2025

Activities · NACE

Groothandel in farmaceutische en medische artikelen

Groothandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗

BAUSCH & LOMB PHARMA

Financials

What happened to BAUSCH & LOMB PHARMA?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions